Our blog

Why did AstraZeneca's Bydureon fail to cut CV risks? A broad patient group, perhaps

admin 14th September 2017 Uncategorised 0

Anyone looking for a heart-helping class effect from GLP-1 diabetes medications wouldn’t be encouraged by the outcomes data AstraZeneca rolled out Thursday for its once-weekly drug Bydureon.

More: Why did AstraZeneca's Bydureon fail to cut CV risks? A broad patient group, perhaps
Source: fierce

FAQ’s

Our Clients

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque sit amet libero magna. Mauris at enim vel nibh scelerisque porttitor id ut leo. Phasellus pretium, leo a lobortis aliquam, nunc tortor pulvinar ipsum, et vulputate lacus tortor a eros. Morbi consequat velit eget augue porttitor vitae molestie diam rutrum.

Management

. Phasellus porta ultrices ante at facilisis. Fusce ornare turpis sit amet lacus egestas elementum. Curabitur risus nunc, consequat ac euismod at, rhoncus in diam. Duis vel rhoncus eros. Phasellus ut neque nec tellus fringilla viverra. Donec pellentesque lectus a quam blandit dictum iaculis mauris ultricies. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Community

Vestibulum ut nunc eu neque mollis accumsan. Fusce est ante, ultrices sed rutrum et, dictum ac nulla. Maecenas posuere bibendum fermentum. Donec iaculis, urna quis pellentesque rhoncus, justo est iaculis diam, pulvinar congue est tellus vel metus. Donec aliquet facilisis sapien. Donec tempor hendrerit purus a dapibus. Praesent aliquet leo ante. Donec non leo lacus, vitae venenatis augue. Vestibulum quam augue, congue a consectetur sed, eleifend a mi.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Our blog

Why did AstraZeneca's Bydureon fail to cut CV risks? A broad patient group, perhaps

Categories

Lorem ipsum

FAQ’s

Our Clients

Management

Community

Archive

Calendar